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IL-15 promotes human myogenesis 
and mitigates the detrimental 
effects of TNFα on myotube 
development
Mary F. O’Leary1, Graham R. Wallace1, Andrew J. Bennett2, Kostas Tsintzas3 &  
Simon W. Jones1
Studies in murine cell lines and in mouse models suggest that IL-15 promotes myogenesis and may 
protect against the inflammation-mediated skeletal muscle atrophy which occurs in sarcopenia and 
cachexia. The effects of IL-15 on human skeletal muscle growth and development remain largely 
uncharacterised. Myogenic cultures were isolated from the skeletal muscle of young and elderly 
subjects. Myoblasts were differentiated for 8 d, with or without the addition of recombinant cytokines 
(rIL-15, rTNFα) and an IL-15 receptor neutralising antibody. Although myotubes were 19% thinner in 
cultures derived from elderly subjects, rIL-15 increased the thickness of myotubes (MTT) from both 
age groups to a similar extent. Neutralisation of the high-affinity IL-15 receptor binding subunit, IL-
15rα in elderly myotubes confirmed that autocrine concentrations of IL-15 also support myogenesis. 
Co-incubation of differentiating myoblasts with rIL-15 and rTNFα, limited the reduction in MTT and 
nuclear fusion index (NFI) associated with rTNFα stimulation alone. IL-15rα neutralisation and rTNFα 
decreased MTT and NFI further. This, coupled with our observation that myotubes secrete IL-15 in 
response to TNFα stimulation supports the notion that IL-15 serves to mitigate inflammatory skeletal 
muscle loss. IL-15 may be an effective therapeutic target for the attenuation of inflammation-mediated 
skeletal muscle atrophy.
Loss of skeletal muscle mass with age (sarcopenia), injury and illness is a major contributor to frailty and dis-
ability in the elderly1,2. Importantly, recent studies in the mouse suggest that IL-15, a 14 kDa four-helix bundle 
cytokine may play a central role in the growth and maintenance of skeletal muscle3–6. However, to date, no studies 
have examined the expression or functional role of IL-15 in human derived skeletal muscle tissue or primary cells.
Stimulation of murine C2C12 myoblasts with recombinant IL-15 (rIL-15) increases myoblast proliferation and 
myosin heavy chain expression, promoting the development of larger myotubes7. Furthermore, ex-vivo stimula-
tion of rat extensor digitorum longus muscle with rIL-15 decreased skeletal muscle proteolytic rate8, suggesting an 
anti-atrophic effect of IL-15 on muscle tissue. Indeed, it is suggested that IL-15 may play an important key role in 
the maintenance of muscle mass in the presence of atrophic stimuli. For example, rIL-15 ameliorated the induction 
of protease (cathepsin L) activity in TNFα and dexamethasone stimulated C2C12 myotubes9. Furthermore, in an 
experimentally-induced sepsis mouse model, rIL-15 reduced the mRNA expression of the E3 ligases MAFbx and 
MuRF-1 which ubiquitinate and target proteins for proteasomal degradation9. rIL-I5 treatment of Yoshida AH-130 
ascites hepatoma rats decreased skeletal muscle protein degradation 8-fold and significantly limited loss of body 
mass as well as soleus and tibalis muscle mass10. It has been proposed that IL-15 is a compensatory factor, expressed 
by skeletal muscle in order to mitigate conditions promoting skeletal muscle atrophy11.
Importantly, current evidence from in vivo human studies points to a crucial role for myogenesis in adult 
skeletal muscle maintenance, hypertrophy and remodelling in response to disuse atrophy as well as injurious and 
non-injurious exercise12. Therefore, in this study we used a model of adult human myoblast differentiation into 
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myotubes to determine the effect of IL-15 on myogenesis. We further sought to establish whether the purported 
myogenic effects of IL-15 are conserved in elderly human skeletal muscle, since IL-15 signalling may represent 
an important pathway for the identification and development of therapeutic approaches designed to preserve 
the loss of skeletal muscle mass and quality in ageing. Given the propensity of the elderly to develop sarcope-
nia, we hypothesised that myogenic cultures derived from the skeletal muscle of elderly individuals would be 
more resistant to the hypertrophic effects of IL-15 than those of young individuals. Finally, we sought to exam-
ine whether IL-15 could protect primary human myotube development from the deleterious effects of TNFα, a 
pro-inflammatory cytokine implicated in the pathogenesis of sarcopenia13 and cachexia in chronic illness14.
Results
Effect of IL-15 on human myotube development and myogenic gene expression. To examine 
the effect of IL-15 on human myotube development, myoblasts from young subjects were differentiated for 8 d in 
the presence of recombinant human IL-15 (rIL-15) at 1, 25 and 100 ng/mL. The resulting myotubes were fixed, 
immunofluorescence (IF) stained for desmin and counterstained with DAPI. Plates were imaged and myogenesis 
quantified by determining myotube thickness (MTT) and nuclear fusion index (NFI).
rIL-15 (100 ng/mL) significantly increased the MTT of differentiated myotubes by 22 ± 5% (p < 0.01) 
(Fig. 1a,b). Stimulation of differentiating myotubes for 8 d with either 25 ng/mL or 100 ng/mL rIL-15 also 
enhanced the NFI (35 ± 4%, p < 0.0001; 45 ± 7%, p < 0.0001 at 25 and 100 ng/mL respectively), compared to 
unstimulated controls (Fig. 1c). Furthermore, the average number of myonuclei in each myotube was enhanced 
by rIL-15 stimulation (114 ± 20%, p < 0.0001; 128 ± 27%, p < 0.0001 at 25 and 100 ng/mL respectively) (Fig. 1d).
We then examined whether IL-15 affected the mRNA expression of known mediators of myogenesis (namely 
myomaker, and the myogenic transcription factors MyoD, myogenin and Myf5) in un-differentiated myoblasts 
and in myoblasts during their differentiation into myotubes. Firstly, myoblasts were stimulated with rIL-15 (at 
1ng/mL or 25 ng/mL) or left unstimulated for 8 d, at which time they had reached 90% confluence. Media were 
renewed every 2 d. Stimulation of myoblasts with rIL-15 (25 ng/mL) induced a small (1.3-fold) but highly signif-
icant (p < 0.0001) increase in the expression of myomaker, a cell membrane protein that is essential for myoblast 
fusion (Fig. 1e). Notably, this alteration in myomaker expression was not accompanied by changes in the expres-
sion of either MYF5, MYOG or MYOD1 expression (Supplementary Fig. 1).
In a separate experiment, myoblasts at 90% confluence were switched to differentiation medium, or to differ-
entiation media containing rIL-15 (at 1 ng/mL or 25 ng/mL). After 8 d of differentiation, myogenic regulatory 
factor gene expression was quantified by RT-qPCR. rIL-15 increased the gene expression of MYOG (1.45-fold, 
p = 0.09; 2.5-fold, p < 0.0001 at 1 and 25 ng/mL respectively) and MYOD (2.36 fold, p = 0.02; 3.32-fold, p < 0.05 
at 1 and 25 ng/mL respectively) in differentiated myotubes (Fig. 1f,g).
Recombinant IL-15 Stimulation of Differentiating Primary Human Myoblasts Partially Reverses 
TNFα-induced Inhibition of Myogenic Differentiation in Young and Old Myotubes. Next we sought 
to determine whether myogenic cultures derived from elderly subjects were also sensitive to the pro-myogenic 
effects of rIL-15 and whether rIL-15 was capable of reversing the deleterious effects of recombinant TNFα (rTNFα) 
on myogenesis using an rTNFα concentration representative of those found systemically in cachexia15,16.
Differentiating myoblasts from young and old subjects were stimulated with either rTNFα (1 ng/mL) alone, 
rIL-15 (25 ng/ml) ± rTNFα (1 ng/mL) or were left unstimulated (controls) over 8 d. Media were renewed every 
2 d. The resulting myotubes were fixed, IF stained and imaged as before (Fig. 2a). Myotubes were 19% thinner 
in cultures derived from elderly subjects. However, rIL-15 increased the MTT of myotubes from elderly donors 
(22 ± 5%, p = 0.02), indicating that they are sensitive to the hypertrophic effects of IL-15 that we observed in the 
young (Fig. 2b). In young myotubes, rTNFα alone induced a 30 ± 5% decrease in myotube thickness (p < 0.0001) 
compared to unstimulated control myotubes. However, co-incubation of differentiating myoblasts with rIL-15 
and rTNFα partially reversed this effect, limiting loss of MTT to 11 ± 6% of the control, a significant improve-
ment compared to the rTNFα alone condition (p = 0.04). In old myotubes, the decrease in MTT induced by 
TNFα was not significant, however, myotubes co-stimulated with TNFα and rIL-15 condition were significantly 
thicker (29 ± 7%, P = 0.001) than their TNFα-stimulated counterparts (Fig. 2b).
rIL-15 alone did not significantly increase the NFI in old myotubes or in this cohort of young myotubes. 
However, in both age groups co-incubation of differentiating myoblasts with rIL-15 and rTNFα completely 
reversed TNFα-induced reductions in NFI, resulting in NFI values which did not differ significantly from the 
control (Fig. 2c). rIL-15 stimulation of proliferating myoblasts had no effect on their proliferation or survival 
rates (Supplementary Fig. 2). Furthermore, in differentiated cultures the number of nuclei per field of view did 
not differ significantly between stimulation conditions, suggesting that their effects on MTT and NFI were not 
due to differences in cell survival, proliferation or errors in cell seeding density (Supplementary Fig. 2). As before 
(Fig. 1), 25 ng/mL rIL-15 induced a substantial and significant increase in the average number of myonuclei in 
each myotube. However, myotubes formed in the presence of rTNFα, did not differ from unstimulated controls 
in their myonuclear number, irrespective of whether they were co-stimulated with rIL-15 (Supplementary Fig. 2).
Having observed pro-myogenic effects of rIL-15 both in the presence and the absence of a pro-inflammatory 
(rTNFα) stimulus, we sought further molecular corroboration for our observations in both undifferentiated myo-
blasts and in differentiating cultures. Subconfluent myoblasts were switched to growth medium containing the 
recombinant cytokines (IL-15, 25 ng/mL; TNFα, 1 ng/mL) or were left unstimulated for 2 d. Immunoblotting 
demonstrated that rIL-15 induced the expression of total ERK 1/2 (p44/42 MAPK), phosphorylated-ERK 
(Thr202/Tyr204) and total Akt. A modest induction of total ERK and phosphorylated ERK expression was 
evident in cultures that were co-stimulated with rIL-15 and TNFα (Fig. 3a). No changes in MyoD, MAFbx or 
MURF-1 expression were observed and myogenin was not detected in these undifferentiated cultures (Fig. 3a).
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Secondly, subconfluent myoblasts were switched to differentiation medium containing the recombinant 
cytokines (IL-15, 25 ng/mL; TNFα, 1 ng/mL) or were left unstimulated for 2d, at which time myotubes begin 
to form in our cultures. Similar to the undifferentiated cultures, stimulation with rIL-15 induced an increase in 
total ERK and phosphorylated ERK expression (Fig. 3b). As expected, myogenin protein could be detected in 
these differentiated cultures, and its expression was increased in cultures stimulated with either rIL-15 or rTNFα, 
compared to unstimulated myotubes (Fig. 3b). In addition, rIL-15 induced an increase in MHC protein con-
tent (Supplementary Fig. 4A), despite not significantly increasing total muscle protein synthesis (Supplementary 
Fig. 4B), as measured using the non-radioactive surface sensing of translation (SUnSET) method17,18.
Elderly individuals display increased skeletal muscle IL-15 expression and increased plasma 
IL-15 concentrations. Cognisant of the suggestion that IL-15 expression increases in order to compen-
sate for conditions that promote skeletal muscle loss11, we quantified circulatory levels of IL-15, as well as the 
Figure 1. Recombinant IL-15 stimulation of differentiating primary human myoblasts enhances myotube 
formation and promotes myogenic gene expression. Subconfluent myoblasts were switched to differentiation 
medium containing the indicated concentrations of IL-15 for 8 d. Media were renewed every 2 d. Myotubes 
were fixed, immunofluorescence stained for desmin and with DAPI and imaged on an epifluorescence 
microscope. (a) Representative images at 20x magnification. (b) Myotube thickness data represents the 
mean ± SEM of 450 total measurements taken at 63x magnification from 90 myotubes per treatment 
condition (n = 3 biological replicates). **p < 0.01 vs. unstimulated (0 ng/mL) condition by Mann-Whitney 
U test with post-hoc Holm’s sequential Bonferroni adjustment. (c) Nuclear fusion index data is expressed as 
mean ± SEM values from 45 images taken at 20x magnification from 3 biological replicates. ***p < 0.001 vs. 
unstimulated (0 ng/mL) condition by one-way ANOVA with post-hoc Bonferroni correction. (d) Number of 
myonuclei per myotube is expressed as mean ± SEM values from 15 images taken at 20x magnification from 3 
biological replicates. (e) Primary human myoblasts were stimulated with recombinant IL-15 at the indicated 
concentrations for 8 days. Media were renewed every 2 d. ***p < 0.001 vs.unstimulated condition by one-way 
ANOVA with post-hoc Bonferroni correction. (f,g) Subconfluent myoblasts were switched to differentiation 
medium containing the indicated concentrations of IL-15 for 8 d. Media were renewed every 2 d *p < 0.05, 
***p < 0.001 vs. unstimulated condition by Mann-Whitney U test with post-hoc Holm’s sequential Bonferroni 
adjustment. Data expressed as mean ± SEM. 3 technical replicates (each assayed in triplicate) per biological 
replicate, 3 biological replicates
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expression of IL-15 and its receptors in young and old skeletal muscle tissue derived from skeletal muscle biop-
sies. Skeletal muscle expression of IL15 was 2-fold higher (Fig. 4a) in old subjects, compared to young subjects. 
Furthermore, circulatory concentrations of IL-15 were significantly greater in older subjects, being ~ 50% higher 
(p = 0.0006) in the old compared to the young (Fig. 4d). However, we also found that the IL-15 receptor signalling 
subunit IL2RB was decreased by ~80% in old skeletal muscle, compared to young, with no change in the expres-
sion of IL15RA (Fig. 4b,c).
TNFα induces IL-15 expression in and its secretion from primary human myotubes. Given that 
IL-15 reverses the anti-myogenic actions TNFα and that IL-15 has been proposed as compensatory agent that 
is expressed in response to atrophic stimuli19, we sought to establish whether an inflammatory stimulus could 
induce IL-15 secretion and expression in primary human myotubes.
Stimulation of primary human myotubes from young subjects with 20 ng/mL rTNFα for 24 h induced 
a 19-fold increase in myotube IL15 expression (p = 0.0004) (Fig. 5a). Myotubes were found to express both 
IL15RA and IL2RB, and 24 h rTNFα stimulation significantly induced the expression of both IL15RA (10-fold; 
p = 0.0014), and IL2RB (126-fold; p = 0.01), relative to non-stimulated control myotubes (Fig. 5b,c). We also 
observed a corresponding 4-fold (p = 0.0006) increase in culture supernatant IL-15 concentration (Fig. 5d), indi-
cating a significant increase in IL-15 secretion from rTNFα stimulated human myotubes.
Antibody neutralisation of IL-15rα eliminates the myogenic effects of IL-15 and enhances the 
detrimental effects of TNFα on myotube development. Given our findings that IL-15 acts to facili-
tate myotube development in an inflammatory environment and that TNFα induces its secretion from primary 
human myotubes, we investigated whether disruption of IL15 binding to its receptor would cause a further dete-
rioration in myogenesis in the presence of TNFα.
We employed an antibody against the IL-15 receptor binding subunit, IL-15rα. Myoblasts from elderly sub-
jects were differentiated for 8 d in the presence of IL-15 (25 ng/mL) or TNFα (1 ng/mL) with the further addition 
of an IL-15rα neutralising antibody (1ug/mL) or an IgG isotype control (1 ug/mL). Media were renewed every 
2 d. The presence of the IL-15rα neutralising antibody significantly reduced the MTT of otherwise untreated 
(24 ± 4%, p = 0.003), IL-15 stimulated (35 ± 3%, p = <0.0001) and TNFα stimulated (17 ± 2%, p = 0.014) 
Figure 2. Recombinant IL-15 stimulation of differentiating primary human myoblasts partially reverses TNFα-
induced inhibition of myogenic differentiation of cells from both young and old individuals. Subconfluent 
myoblasts were switched to differentiation medium containing the indicated recombinant cytokines (IL-15, 25 
ng/mL; TNFα, 1 ng/mL) for 8 d. Media were renewed every 2 d. Myotubes were fixed, immunofluorescence 
stained for desmin and DAPI and imaged on an epifluorescence microscope. (a) Representative images at 20x 
magnification. (b) Myotube thickness data represents the mean ± SEM of 450 total measurements taken at 
63x magnification from 90 myotubes per treatment condition (from 3 biological replicates). (c) Nuclear fusion 
index data represents the mean ± SEM values from 45 images taken at 20x magnification (from 3 biological 
replicates). *p < 0.05, **p < 0.01, ***p < 0.001 vs. unstimulated condition by 2-way ANOVA with post-hoc 
Bonferroni correction.
www.nature.com/scientificreports/
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myotubes compared to their IgG isotype treated controls (Fig. 6a). The IL-15rα neutralising antibody had a 
similar effect on NFI, although the numerically considerable reduction in NFI observed in TNFα stimulated 
myotubes (56 ± 21%, p = 0.16) treated with a IL-15rα neutralising antibody did not reach significance (Fig. 6b). 
The average number of myonuclei in each myotube was not significantly altered by any treatment condition 
(Supplementary Fig. 5).
Discussion
We have demonstrated for the first time that IL-15 enhances human myotube development and can partially 
protect against the deleterious effects of TNFα on myogenesis. Secretion of IL-15 by primary human myotubes 
derived from patients with polymyositis and dermatomyositis has been previously described20. Here we show for 
the first time that myotubes derived from the skeletal muscle of healthy subjects also secrete IL-15. These data are 
a significant advancement on previous in vitro work describing the effects of IL-15 on skeletal muscle growth and 
maintenance as we have used primary human myogenic cultures, rather than an immortalised murine cell line.
Our studies were primarily designed to firstly examine the functional effect of IL-15 in human myogenesis 
and revealed that IL15 had a marked effect on increasing MTT, NFI and the number of myonuclei per myotube 
(Fig. 1). The magnitude of these changes (a 22% increase in MTT at the 100 ng/mL dose of rIL-15) is consid-
erable when placed in an integrated physiological context. A previous study in humans has shown that even a 
small reduction in quadriceps lean mass following limb immobilisation (5% over 2 weeks) is accompanied by a 
significant decline in isometric strength21. Furthermore, 12 weeks of progressive resistance training in older men 
increases MHC I fibre diameter by 20%, a change which is associated with a 55% increase in maximal isometric 
force production by individual muscle fibres22. We also observed that myotubes were 19% thinner in our cultures 
derived from elderly subjects compared to young subjects.
The IL-15-mediated increase in MTT is unlikely to be due to induction of myoblast hyperplasia as we found 
no effect of IL-15 on either the proliferation or viability of subconfluent myoblasts. This is in agreement with 
previous observations that IL-15 has no effect on proliferation, as measured by [3H]thymidine incorporation in 
Figure 3. Recombinant IL-15 stimulation of primary human myogenic cultures induces molecular changes that 
suggest it has pro-myogenic actions. (a) Commercially available subconfluent myoblasts from a female aged 
21 yr were switched to growth medium containing the indicated recombinant cytokines (IL-15, 25 ng/mL;  
TNFα, 1 ng/mL) for 2 d. The expression of the indicated proteins was determined by immunoblotting. Full-
length blots are presented in Supplementary Figure 6. Blots are representative of duplicate independent 
experiments. (b) Commercially available subconfluent myoblasts from a female aged 21 yr were switched to 
differentiation medium containing the indicated recombinant cytokines (IL-15, 25 ng/mL; TNFα, 1 ng/mL) 
for 2 d. The expression of the indicated proteins was determined by immunoblotting. Full-length blots are 
presented in Supplementary Figure 6. Blots are representative of duplicate independent experiments.
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C2C12 myoblasts7. Instead, the hypertrophic mechanism appears to be via an enhancement of myoblast fusion 
and the myogenic program, since we observed a >30% increase in the NFI and a greater than 2-fold increase 
in the number of myonuclei in myotubes formed under IL-15 stimulation conditions. This notion of enhanced 
myogeneis is supported by our finding of total Akt induction in IL-15-stimulated confluent myoblasts that were 
ready for myogenic differentiation. Induction of total Akt expression (in particular that of Akt2) is essential for 
full myotube development23. Furthermore, we observed an increase in total ERK 1/2 and phosphorylated-ERK 
expression in IL-15 stimulated myoblasts. Myogenic cultures appear to have a biphasic requirement for ERK1/2 
activity; ERK 1/2 appears to inhibit differentiation in proliferating cultures, but its activity facilitates myotube for-
mation in differentiating cultures24. Given that these myoblasts had reached a confluence sufficient for myogenic 
differentiation, it is reasonable to hypothesise that ERK 1/2 activation by IL-15 might promote their fusion. This 
requires further study.
Furthermore, IL-15 induced an increase in myomaker gene expression in confluent myoblasts that were ready 
for myogenic differentiation. Myomaker is a recently discovered muscle-specific cell membrane protein that has 
been reported to be essential for myoblast fusion and muscle regeneration25,26. Most recently, myomaker depend-
ent myoblast fusion to existing myofibres has been shown to be essential for overload-induced hypertrophy to 
occur in mice27. The finding that myomaker expression increased in IL-15 stimulated myoblasts represents a 
potentially novel mechanism of myogenic action for IL-15 in human skeletal muscle. In chicken myoblasts, the 
myogenic regulatory factors (MRFs) MYOG and MYOD have been shown to bind to an E-box near the myo-
maker transcription start site, thus inducing myomaker expression28. Indeed, IL-15 induced an increase in the 
expression of both MYOD and MYOG in differentiated myotubes.
Ageing is associated with a loss of skeletal muscle mass and quality – sarcopenia29. Given that our myotubes 
from elderly subjects formed less well than those from their young counterparts, we hypothesised that elderly 
cultures might be less sensitive to the myogenic actions of IL-15. However, we observed no difference in the 
functional responsiveness to exogenous rIL-15 stimulation between old and young myotubes, demonstrating 
that IL-15 signalling is not functionally impaired in the elderly. Despite observing no difference in the functional 
responsiveness to exogenous rIL-15 stimulation between young and old myotubes we did observe that the skele-
tal muscle tissue expression of the signalling subunit of the IL-15 receptor (IL2RB) was found to be significantly 
reduced in the elderly, compared to the young subjects. However, the expression of the IL-15 receptor binding 
subunit, IL15RA was maintained. Given its high affinity for IL-15 compared to the signalling subunit. mainte-
nance of IL15RA expression may compensate for the reduction in IL2RB expression.
Importantly, evidence from in vivo human studies suggest an important role for myogenesis in adult skel-
etal muscle12. Therefore, our finding that IL-15 also promotes myoblast fusion in developing primary human 
myofibres derived from old subjects is particularly pertinent. Furthermore, one purpose of neutralising the 
high-affinity IL-15 receptor binding subunit, IL-15rα in elderly myotubes was to confirm that the pro-myogenic 
Figure 4. Elderly individuals display increased skeletal muscle IL-15 expression and increased plasma IL-15 
concentrations. (a,b,c) IL15, IL15RA and IL2RB gene expression were quantified in skeletal muscle tissue by RT-
PCR. **p < 0.01, vs. unstimulated condition by Mann-Whitney U test, N = 5. (d) Plasma IL-15 concentrations 
were assayed by ELISA. ***p < 0.001 vs. the unstimulated condition by t-test. Data expressed as mean ± SEM, 
N = 10.
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activity of IL-15 in elderly individuals is not limited to the pharmacological doses of the recombinant cytokine 
used by ourselves and others9,30. Our neutralisation of the receptor was successful; it completely inhibited the 
myogenic actions of exogenous rIL-15 (Fig. 6). In otherwise unstimulated elderly myotube cultures, IL-15rα neu-
tralisation had a deleterious effect on myogenesis, suggesting that autocrine IL-15 secretion in elderly myotubes 
is crucial to support optimal myotube formation.
Given the emerging importance of inflammation in the aetiology of sarcopenia13, and its pathological role in 
cachexia14 it is remarkable and of potential clinical importance that IL-15 proved capable of ameliorating the dele-
terious effects of TNFα on primary human myotube development, regardless of culture donor age (Fig. 2). TNFα 
is known to induce myotube atrophy31 and its plasma levels increase with age, independent of BMI32. Given the 
positive myogenic actions of IL-15, we hypothesise that the observed TNFα-mediated induction of IL-15 secre-
tion and expression of IL15 and its receptor subunits IL15RA and IL2RB (Fig. 4), may represent a homeostatic 
mechanism, whereby IL-15 is induced to facilitate skeletal muscle maintenance in the presence of inflammation 
e.g. in inflammaging or in chronic clinical conditions that are associated with cachexia33. Indeed, we observed 
that MTT was decreased to an even greater degree by TNFα in the presence of a neutralising IL-15rα antibody 
(Fig. 6a), supporting the notion that IL-15 serves as compensatory factor in highly inflammatory environments. 
The induction of IL-15 secretion from TNFα stimulated myofibres might also, in part, explain why concentrations 
of TNFα in the normal physiological range have been reported to support myotube formation34. It is important 
to note that despite clearly demonstrating the pro-myogenic actions of IL-15, we have not fully established the 
molecular mechanism by which IL-15 ameliorates the detrimental effects of TNFα on myogenesis. It may be that 
that IL-15 remains pro-myogenic in the presence of TNFα. However, our molecular signalling analysis showed 
that the IL-15-mediated induction of pERK and of total AKT was markedly diminished by the presence of TNFα 
(Fig. 3a,b). Furthermore, unlike with IL-15 stimulation alone, co-stimulation of differentiating myotubes with 
IL-15 and TNFα did not increase the number of myonuclei per myotube (Supplementary Fig. 2D,E).
In summary, we have provided evidence for the first time that IL-15 enhances in vitro human myogenesis and 
can partially protect against the deleterious effects of TNFα on human myotube development. Targeting the IL-15 
signalling pathway may therefore be an effective therapeutic approach in combating skeletal muscle atrophy, par-
ticularly in inflammatory disease states.
Figure 5. Stimulation of primary human myotubes with recombinant TNFα induces IL-15/L-15 receptor gene 
expression and the secretion of IL-15. Primary human myotubes were stimulated with recombinant TNFα  
(20 ng/mL) for 24 hours. (a,b,c) IL15, IL15RA and IL2RB gene expression were quantified by RT-PCR. 
**p < 0.01, ***p < 0.001 vs. unstimulated condition by Mann-Whitney U test. 3 technical replicates (each 
assayed in triplicate) per biological replicate, 3 biological replicates. (d) Supernatant IL-15 concentrations were 
assayed by ELISA. ***p < 0.001 vs. unstimulated condition by one-way ANOVA with post-hoc Bonferroni 
correction. Data expressed as mean ± SEM; 5 technical replications per biological replicate, 3 biological 
replicates.
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Experimental Procedures
Subject Recruitment and Ethical Approval. Ten young healthy subjects (5 males and 5 females; age 
21.8 ± 0.5; weight 59.6 ± 3.3 kg; BMI 21.4 ± 0.9 kg/m2) and five elderly healthy individuals (3 males and 2 females; 
age 69.9 ± 2.3; weight 69.7 ± 10.5 kg; BMI 23.8 ± 2.3 kg/m2) were enrolled in this study and gave written informed 
consent. The study was approved by the University of Nottingham Medical School Ethics Committee and was 
conducted in accordance with the guidelines of the Declaration of Helsinki. Samples for the quantification of 
plasma IL-15 were obtained from healthy young and old subjects in a study that was approved by the Birmingham 
East North and Solihull Research Ethics Committee (09/H1206/48) and all subjects gave their written informed 
consent before taking part in the study.
Tissue Collection and Cell Culture. A vastus lateralis muscle biopsy was obtained from each subject using 
the suction-modified Bergström technique35 and the satellite cell population extracted. Briefly, samples were 
minced with a scalpel and digested on an orbital rotator for 15 min at 37 °C. 5 mL growth medium (Ham’s F10 
with 2mM L-glutamine, 100 μg/mL penicillin/streptomycin, 20% FBS) was added and the digest centrifuged at 
460 g for 5 min. The resulting pellets were resuspended in growth medium and incubated for 20 min at 37 °C, 
5% CO2 in an uncoated T75 tissue culture flask. The cell suspension was removed to flasks or plates coated with 
0.2% gelatin and the myoblasts cultured in growth medium. Myoblasts were subcultured (1:3) at 70% confluence 
by trypsin-induced dissociation from their vessel and were used experimentally at passages 2-4. Myoblasts at 
90% confluence were differentiated to myotubes by switching to differentiation medium (Ham’s F10 with 2mM 
L-glutamine, 100 μg/mL penicillin/streptomycin, 6% horse serum) for 8 d. Media were renewed every 2 d. One 
concern in the generation of primary myogenic cultures is obtaining cultures that are free from the most likely 
Figure 6. Antibody neutralisation of IL-15rα eliminates the myogenic effects of IL-15 and enhances the 
detrimental effects of TNFα on myotube development. Subconfluent myoblasts were switched to differentiation 
medium containing the indicated recombinant cytokines and antibodies (IL-15, 25 ng/mL; TNFα, 1 ng/mL; 
IL-15rα antibody, 1 µg/mL; IgG1 antibody, 1 µg/mL) for 8 d. Media were renewed every 2 d. Myotubes were 
fixed, immunofluorescence stained for desmin and DAPI and imaged on an epifluorescence microscope. (a) 
Myotube thickness data represents the mean ± SEM of 450 total measurements taken at 63x magnification from 
90 myotubes per treatment condition (from 3 biological replicates). (b) Nuclear fusion index data represents 
the mean ± SEM values from 45 images taken at 20x magnification (from 3 biological replicates). *p < 0.05, 
***p < 0.001 vs. IgG control condition by t-test.
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contaminating cell type – fibroblasts36,37. Our isolation technique has consistently produced cultures in our lab 
that produce desmin positive multinucleated myotubes (Figs 1,2) that are negative for the fibroblast marker TE738 
(Supplementary Fig. 7).
Additionally, commercially available primary human myoblasts (Thermo Fisher cat. No. A12555), isolated 
from a female aged 21 yr were used for the immunoblotting work presented in Fig. 3 and Supplementary Fig. 4. 
They were cultured in the same media and conditions as the cultures that we isolated in-house.
Immunofluorescence Staining. Myotubes were differentiated for 8 d in 24-well culture plates in the pres-
ence of rIL-15 (0, 1, 25, 100 ng/mL), rTNFα (0, 1 ng/mL) or both cytokines (rIL-15 25 ng/mL and rTNFα 1 ng/mL). 
Media were renewed every 2 d. The culture medium was removed and the cells fixed with 2% formaldehyde 
in PBS for 30 min. Following permeabilization in 100% methanol for 10 min, wells were blocked with 5% goat 
serum in PBS for 30 min. Primary antibodies were diluted (Desmin, 1:1000, Dako) in 1% BSA/PBS and 150 μL 
was added per well for 1 hour. Wells were subsequently incubated with 150 μL/well secondary antibody (Goat 
anti-Mouse IgG (H + L), Alexa Fluor® 488 conjugated, Thermo Fisher) for 1 hour in the dark. Each well was 
washed with PBS and 150 μL/well DAPI/PBS (1:5000, Cell Signalling Technology) was added for 5 min in the 
dark. Wells were further washed with PBS, a drop of mountant added to each well (ProLong Diamond Antifade, 
Thermo Fisher) and a coverslip applied.
Quantification of Myotube Thickness, Myotube Number and Nuclear Fusion index. 24-well 
plates of IF stained myotubes were imaged on an epifluorescence/brightfield microscope (Leica DMI6000). 
Triplicate wells were stimulated for each biological replicate and for each treatment condition. Multiple images 
were taken in each well for the quantification of MTT and NFI. For quantification of MTT, 15 images of each 
well were obtained using the 63x objective, the first image being obtained at a fixed starting point and subsequent 
images selected by moving to the next field of view in a predefined pattern. For assessment of NFI, 5 images of 
each well were obtained in the same fashion, using the 20x objective. Image analysis was carried out by a blinded 
researcher, using Image J software39–52. A myotube was defined as a desmin positive object, containing 3 or more 
nuclei. The MTT each myotube was calculated by taking the average of 5 measurements obtained along its length. 
The NFI was defined as the number of nuclei clearly incorporated into myotubes expressed as a proportion of the 
total visible nuclei in each field of view.
Real Time Quantitative Polymerase Chain Reaction. RNA was extracted using TRIzol® Reagent (Life 
Technologies) according to the manufacturer’s instructions. A microvolume spectrophotometer (Nanodrop 2000, 
Thermo Fisher) was used to quantify each RNA sample and to determine its quality. RNA was reverse transcribed, 
amplified and quantified in triplicate using Precision Onestep qRT-PCR Mastermix premixed with SYBR greem 
(Primerdesign) on a Lightcycler 480 instrument (Roche). The primer sequences for each gene are detailed in 
Supplementary Table 1. Relative RNA expression was determined by the ddCT method, normalized to ACTB 
expression.
Immunoblotting. For protein extraction, myotubes were lysed in ice-cold RIPA buffer (50 mM Tris HCl, 
150 mM NaCl, 1.0% (v/v) NP-40, 0.5% (w/v) Sodium Deoxycholate, 1.0 mM ethylenediaminetetraacetic acid 
[EDTA], 0.1% (w/v) sodium dodecyl sulfate [SDS], 0.01% (w/v) sodium azide, pH of 7.4), containing a pro-
tease and a phosphatase inhibitor cocktail. Total protein lysates of known concentration (bicinchoninic acid 
assay, Thermo Scientific) were prepared in 4x Laemmli sample loading buffer (0.5 M Tris-HCl pH 6.8, 20% (v/v) 
Glycerol, 10% (w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) beta-mercaptoethanol [βME]) and water to 
generate loading stocks of known concentration. Samples were boiled for 5 min before loading. SDS polyacryla-
mide gel electrophoresis (SDS-PAGE) gels (12% w/v) were cast in empty gel loading cassettes (Thermo Fisher)
Equal amounts of total protein were loaded onto SDS-PAGE gels. Proteins were separated by electropho-
resis (50 mA) in 1x Tris-Glycine SDS-PAGE Buffer (0.025 M Tris base, 0.192 M glylcine, and 0.1% (w/v) SDS). 
Proteins were then transferred onto polyvinylidene difluoride (PVDF) membrane (Amersham Hybond-P, GE 
Healthcare) in an electroblotting buffer (0.025 M Tris base, 0.192 M glylcine, 20% (v/v) methanol at pH 8.4), 
using the ‘Standard SD’ program of the Trans-Blot Turbo semi-dry transfer system (Bio-Rad). Membranes were 
blocked for 1 h and agitated overnight with primary antibody diluted in tris buffered saline with 0.1% Tween 
20 (TBS-T; 50 mM Tris hydrochloride [Tris-HCl], 150 mM sodium chloride [NaCl], 0.1% (v/v) Tween 20 at pH 
7.5) at 4 °C (Supplementary Table 2). The membranes were washed for 4 × 5 min in 1xTBS-T and agitated for 
1 h at room temperature with HRP-conjugated secondary antibody (Supplementary Table 2). TBS-T washes 
were repeated and the membranes incubated with ECL Prime Western blotting detection reagents (Amersham 
Biosciences) according to the manufacturer’s instructions. Blots were visualised on the ChemiDoc MP imaging 
system (Bio-Rad).
Enzyme-Linked Immunosorbent Assay. Myotubes were stimulated with 20 ng/mL TNFα. Cell cul-
ture supernatants were collected and stored at −80 °C. Supernatant IL-15 concentrations were quantified using 
Human Quantikine ELISA kits (R&D Systems), according to the manufacturer’s instructions.
Cell Proliferation Assay. Myoblasts were seeded onto 0.2% gelatin-coated 96-well plates at a density of 
2000 cells per well and were stimulated with the indicated recombinant cytokines (IL-15, 25 ng/mL; TNFα, 1 
ng/mL in myoblast growth medium). The medium was changed every 48 h and the number of viable cells in 
culture assessed at days 1, 3, 6 and 9 using the CellTiter 96® Aqueous One Solution MTS Cell Proliferation Assay 
(Promega) according to the manufacturer’s instructions.
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Non-Radioactive Surface Sensing of Translation (SUnSET) Protein Synthesis Assay. A SUnSET 
protein synthesis assay was employed18. Myotubes were differentiated for 2 d in 24-well culture plates in the 
presence of rIL-15 (0, 1, 25, 100 ng/mL), rTNFα (0, 1 ng/mL) or both cytokines (rIL-15 25 ng/mL and rTNFα 
1 ng/mL). At 2 d, the culture medium was removed and replaced with differentiation medium containing 1 μM 
puromycin (Sigma Aldrich) for 30 min. Cultures were then prepared for immunoblotting (see above) and the 
resulting blots were probed with an anti-puromycin primary antibody (Supplementary Table 2). Protein synthesis 
was estimated by densitometric analysis of each lane, corrected for ponceau stain densitometry values.
Statistical Analysis. Data analysis was carried out using IBM SPSS Statistics 21. All data are presented as 
means ± SEM. The normality of data was established by a Shapiro-Wilk test, whereas Levene’s test was used to 
establish equality of variances. For parametric data involving two treatment conditions unpaired t tests were used. 
Non-parametric data were analysed by Mann-Whitney U tests. Where data involving more than two treatment 
conditions were normally distributed, comparison was performed by a one-way or two-way analysis of variance 
(ANOVA) with post-hoc Bonferroni correction. Where such data were non-parametric, differences between con-
ditions were analysed by Mann –Whitney U test with post-hoc Holm’s sequential Bonferroni correction. A p 
value of <0.05 was considered statistically significant. Details of the statistical tests used for each data set can be 
found in the relevant figure legend.
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